Last reviewed · How we verify

NESP(Darbepoetin alfa) — Competitive Intelligence Brief

NESP(Darbepoetin alfa) (NESP(Darbepoetin alfa)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA). Area: Hematology/Oncology.

phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology/Oncology Biologic Live · refreshed every 30 min

Target snapshot

NESP(Darbepoetin alfa) (NESP(Darbepoetin alfa)) — Chong Kun Dang Pharmaceutical. Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NESP(Darbepoetin alfa) TARGET NESP(Darbepoetin alfa) Chong Kun Dang Pharmaceutical phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR)
Epogen Epoetin Alfa-Epbx Amgen marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor 1989-01-01
epoetin epoetin Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor
continuation (darbepoetinum) continuation (darbepoetinum) Anemia Working Group Romania marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR)
epoetin beta [NeoRecormon] epoetin beta [NeoRecormon] Hoffmann-La Roche marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR)
Epoetin β (450 UI/kg/week) Epoetin β (450 UI/kg/week) Germans Trias i Pujol Hospital marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR)
Erythropoietin carried on chitosan carrier Erythropoietin carried on chitosan carrier Ain Shams University marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA) class)

  1. Amgen · 4 drugs in this class
  2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 3 drugs in this class
  3. Hospital de Clinicas de Porto Alegre · 2 drugs in this class
  4. Pfizer · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Chong Kun Dang Pharmaceutical · 2 drugs in this class
  7. Barts & The London NHS Trust · 1 drug in this class
  8. Australian and New Zealand Intensive Care Research Centre · 1 drug in this class
  9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  10. Biocad · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NESP(Darbepoetin alfa) — Competitive Intelligence Brief. https://druglandscape.com/ci/nesp-darbepoetin-alfa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: